Compare Abeona Therapeutics Inc (ABEO) vs Lennar Corporation (LEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lennar Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Lennar Corporation trades at $83.94 (market cap $20.84B). The key difference: Lennar Corporation is far larger — about 55.8× Abeona Therapeutics Inc's market cap, and Lennar Corporation pays a 2.31% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | LEN | |
|---|---|---|
Market Cap | $373.32M | $20.84B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $142.40 |
52-Week Low | $4.17 | $82.30 |
Enterprise Value | $228.22M | $24.72B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Lennar (LEN) trades at $86.74, down 1.67% on the day, with a bearish technical signal despite appearing undervalued on key metrics (P/E 13.83, P/S 0.67). Recent earnings have missed expectations, with Q2 2026 EPS expected at 1.32. The company faces margin pressure as it prioritizes sales volume over price, cutting average home prices to 2017 levels to boost affordability amid high mortgage rates.
While Lennar's valuation appears attractive and analyst consensus leans bullish (46% buy ratings), near-term risks include persistent housing affordability challenges, declining profit margins, and negative cash flow trends. Execution on margin recovery through cost discipline and faster cycle times will be crucial for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
